First-Line Chemotherapy: Pemetrexed Plus Cisplatin
Pemetrexed combined with cisplatin is the established first-line chemotherapy for advanced malignant pleural mesothelioma. This combination was approved based on the phase III EMPHASIS trial (Vogelzang et al., 2003) and remains the standard backbone of treatment.
Survival Data from Clinical Trials
| Treatment | Median Overall Survival | Response Rate |
|---|---|---|
| Pemetrexed + Cisplatin | 12.1 months | 41.3% |
| Cisplatin alone | 9.3 months | 16.7% |
The hazard ratio of 0.77 (p=0.020) represents a statistically significant survival benefit for the combination therapy.
How Chemotherapy Works
Pemetrexed is an antifolate that disrupts cancer cell DNA synthesis. Cisplatin is a platinum compound that damages DNA and triggers cell death. Together, they:
- Slow tumor growth
- Reduce pleural fluid accumulation
- Improve breathing and reduce chest pain
- Extend survival compared to best supportive care
Carboplatin as Alternative
For patients who cannot tolerate cisplatin due to kidney impairment or other toxicity, carboplatin may substitute. Both platinum agents show similar efficacy, though cisplatin remains preferred when tolerable.
Response Rates by Cell Type
Chemotherapy effectiveness varies significantly based on mesothelioma histology. The CheckMate-743 trial provides the clearest data:
| Cell Type | Chemotherapy Median Survival | Notes |
|---|---|---|
| Epithelioid | 16.5 months | Best response to chemotherapy |
| Sarcomatoid/Biphasic | 8.8 months | Chemoresistant |
Why Cell Type Matters
Epithelioid mesothelioma (60-70% of cases) responds better to chemotherapy, with response rates of 30-40%, more predictable tumor behavior, and better outcomes when chemotherapy is combined with surgery. Sarcomatoid mesothelioma (10-20% of cases) is notably chemoresistant, with response rates under 20% and aggressive tumor biology. People with sarcomatoid disease may benefit more from nivolumab-ipilimumab than from chemotherapy. Biphasic mesothelioma contains both cell types, with outcomes depending on the proportion of each.
Managing Side Effects
Chemotherapy affects fast-growing healthy cells, causing predictable side effects. Most can be managed with supportive care.
Common Side Effects
Blood-related:
- Low white blood cells (increased infection risk)
- Low red blood cells (fatigue, anemia)
- Low platelets (bleeding risk)
Gastrointestinal:
- Nausea and vomiting
- Loss of appetite
- Constipation or diarrhea
- Mouth sores
Neurological:
- Neuropathy (numbness, tingling in hands/feet)
- “Chemo brain” (cognitive changes)
- Fatigue
Other:
- Hair thinning (less common with this regimen)
- Kidney changes
- Weight loss
Supportive Care Strategies
| Side Effect | Management |
|---|---|
| Nausea/vomiting | Ondansetron, aprepitant, dietary changes |
| Infection risk | Filgrastim (growth factor), avoiding crowds |
| Neuropathy | Gabapentin, duloxetine |
| Mouth sores | Saline rinses, avoiding spicy foods |
| Loss of appetite | Megestrol acetate, nutritional counseling |
| Fatigue | Gentle exercise, energy conservation |
Folic acid and vitamin B12 supplementation is required with pemetrexed to reduce serious toxicity. Your oncologist will prescribe folic acid daily (starting 1 week before treatment) and vitamin B12 injection every 9 weeks.
Chemotherapy Combined with Surgery
Multimodal treatment, combining chemotherapy with surgery, can significantly extend survival in appropriate candidates.
Chemotherapy Before Surgery (Neoadjuvant)
Neoadjuvant chemotherapy is given before surgery to shrink tumors for easier removal, test how the tumor responds to treatment, and help identify which patients are likely to benefit from surgery.
Chemotherapy After Surgery (Adjuvant)
Adjuvant chemotherapy is given after surgery to target microscopic residual disease, reduce the risk of recurrence, and extend disease-free survival.
Cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC) produces exceptional results for peritoneal mesothelioma, with 5-year survival rates up to 50% when complete cytoreduction is achieved. Dr. Paul Sugarbaker at MedStar Washington Hospital Center pioneered the CRS + HIPEC approach for peritoneal disease in the 1990s.
Outcomes with CRS Plus HIPEC
Cytoreductive surgery combined with HIPEC:
| Outcome | Result |
|---|---|
| Median survival with CRS + HIPEC | 28-34 months |
| 5-year survival (complete cytoreduction) | Up to 50% |
| Median survival (synchronous disease with neoadjuvant) | 28 months |
A 2025 study by Framarini et al. found neoadjuvant chemotherapy showed a protective effect (HR=0.09) in people with peritoneal mesothelioma undergoing CRS + HIPEC.
Second-Line Options After Progression
When first-line pemetrexed-cisplatin stops working, several options exist:
Gemcitabine
Gemcitabine (Gemzar) is the primary second-line chemotherapy option. It works through a different mechanism than first-line drugs and can extend survival in late-stage disease, either alone or in combination with other agents.
Vinorelbine
Vinorelbine is sometimes used as second-line therapy, particularly for people who cannot tolerate gemcitabine, as a combination regimen, or within a clinical trial. The UK CONFIRM trial (NCT03063450) and the VIM trial both examined vinorelbine-based approaches.
Retreatment with Pemetrexed
For people who responded well initially and had a prolonged treatment-free interval, rechallenge with pemetrexed plus a platinum agent is sometimes considered.
Chemotherapy Plus Immunotherapy
Combining chemotherapy with immunotherapy is an active area of research showing promising results.
KEYNOTE-483 Trial (Pembrolizumab + Chemotherapy)
| Outcome | Combination | Chemotherapy Alone |
|---|---|---|
| Median survival | 17.3 months | 16.1 months |
| 3-year survival | 25% | 17% |
CheckMate-743 (Dual Immunotherapy vs Chemotherapy)
The landmark CheckMate-743 trial compared nivolumab plus ipilimumab to chemotherapy:
| Outcome | Immunotherapy | Chemotherapy |
|---|---|---|
| Median survival | 18.1 months | 14.1 months |
| 2-year survival | 41% | 27% |
| 3-year survival | 23% | 15% |
This led to FDA approval of nivolumab-ipilimumab as first-line treatment.
Choosing Between Options
The decision turns on several factors. Cell type matters (sarcomatoid disease may benefit more from immunotherapy), as does PD-L1 status, which can predict immunotherapy response. Age, performance status, and personal preferences weigh heavily, and immunotherapy is often better tolerated than platinum chemotherapy. The CheckMate 743 data specifically showed nivolumab plus ipilimumab outperformed chemotherapy in non-epithelioid disease.
Treatment Timeline
Typical Chemotherapy Schedule
Each cycle runs 21 days, with drugs administered on day 1. People usually receive 4 to 6 cycles initially, and maintenance therapy may continue if the tumor is responding.
What to Expect
Before each cycle, the care team runs blood tests to check counts, assesses kidney function, and reviews symptoms. On treatment day, people receive vitamin supplementation, anti-nausea pre-medication, IV pemetrexed (infused over about 10 minutes) and cisplatin (a longer infusion), along with hydration to protect the kidneys. Between cycles, the priorities are reporting fevers or infections immediately, managing side effects as directed, and maintaining nutrition and hydration.
What is my mesothelioma cell type, and how does it affect treatment choice?▼
Cell type significantly impacts chemotherapy response. Epithelioid mesothelioma responds best (16.5 months median survival), while sarcomatoid is chemoresistant (8.8 months). Your oncologist can explain what your cell type means for your treatment plan.
Am I a candidate for chemotherapy plus immunotherapy?▼
Combining chemotherapy with immunotherapy is an active area of research. Factors include your cell type, PD-L1 status, performance status, and preferences. Sarcomatoid tumors may benefit more from immunotherapy.
If I progress on first-line treatment, what second-line options exist?▼
Options include gemcitabine, vinorelbine, or rechallenge with pemetrexed-platinum if you had a prolonged response initially. Clinical trials may also offer newer combinations.
What side effects should prompt me to call immediately?▼
Report fevers over 100.4°F, severe nausea/vomiting, bleeding, signs of infection, severe shortness of breath, or any new neurological symptoms immediately.
Should I consider a clinical trial with newer combinations?▼
Clinical trials offer access to promising treatments like ADI-PEG20, which quadrupled 3-year survival in the ATOMIC-MESO trial. Ask about trials you may qualify for.
Emerging Research
ATOMIC-MESO Trial
Pegargiminase (ADI-PEG20) combined with pemetrexed-cisplatin quadrupled 3-year survival rates versus chemotherapy alone in this phase III trial, a potentially important shift in first-line treatment for argininosuccinate synthetase-deficient tumors.
Biomarker Development
Researchers are working to identify:
- Predictive markers for chemotherapy response
- Tumor characteristics guiding treatment selection
- Gene expression profiles for personalized therapy